Publications by authors named "Tom Rolf"

Claim this Profile
S
Safety and immunogenicity of the adjunct therapeutic vaccine ID93 + GLA-SE in adults who have completed treatment for tuberculosis: a randomised, double-blind, placebo-controlled, phase 2a trial.
Tracey A Day, Adam Penn-Nicholson, Angelique Kany Kany Luabeya, Andrew Fiore-Gartland, Nelita Du Plessis, Tom A Rolf

Lancet Respir Med· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase 1 antigen dose escalation trial to evaluate safety, tolerability and immunogenicity of the leprosy vaccine candidate LepVax (LEP-F1 + GLA-SE) in healthy adults.
Malcolm S Duthie, Aude Frevol, Tracey Day, Rhea N Coler, Julie Vergara, Tom Rolf

Vaccine· February 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial.
Rhea N Coler, Tracey A Day, Ruth Ellis, Franco M Piazza, Anna Marie Beckmann, Tom Rolf

NPJ Vaccines· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A structure-function approach to optimizing TLR4 ligands for human vaccines.
Darrick Carter, Christopher B Fox, Tracey A Day, Jeffrey A Guderian, Hong Liang, Tom Rolf

Clin Transl Immunology· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.
Rhea N Coler, Malcolm S Duthie, Kimberly A Hofmeyer, Jeffery Guderian, Lakshmi Jayashankar, Tom Rolf

Clin Transl Immunology· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis